The WACC of Hanall Biopharma Co Ltd (009420.KS) is 7.2%.
| Range | Selected | |
| Cost of equity | 5.70% - 8.70% | 7.20% |
| Tax rate | 6.90% - 40.50% | 23.70% |
| Cost of debt | 4.00% - 7.00% | 5.50% |
| WACC | 5.7% - 8.6% | 7.2% |
| Category | Low | High |
| Long-term bond rate | 3.1% | 3.6% |
| Equity market risk premium | 5.8% | 6.8% |
| Adjusted beta | 0.46 | 0.67 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 5.70% | 8.70% |
| Tax rate | 6.90% | 40.50% |
| Debt/Equity ratio | 0 | 0 |
| Cost of debt | 4.00% | 7.00% |
| After-tax WACC | 5.7% | 8.6% |
| Selected WACC | 7.2% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 009420.KS:
cost_of_equity (7.20%) = risk_free_rate (3.35%) + equity_risk_premium (6.30%) * adjusted_beta (0.46) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.